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Abstract
Background: Recently, more and more evidences have revealed the association between CD44V6 and osteosarcoma
(OS), but whether it can be used as a clinical biomarker is still unknown. The purpose of this study is to assess the
diagnostic value of CD44V6 in OS by conducting a meta-analysis.
Methods: All relevant electronic literatures were collected from seven international databases together with three
Chinese databases up to April 23, 2016. Eligible studies were selected through multiple search strategies and the
quality was assessed by QUADAS. Data was extracted from studies according to the key statistics index. All analyses
were performed using STATA 12 and Meta-DiSc 1.4 statistical software.
Results: According to the exclusion and inclusion criteria, 8 literatures were retrieved, accounting for 463 cases and 188
controls. For discriminating OS from benign bone tumor or healthy controls, the area under the receiver operating
characteristic curve (AUC) was 0.91 (95 % CI 0.88–0.93). Overall, the results showed pooled sensitivity of 0.743 (95 % CI 0.
606–0.844) and specificity of 0.897 (95 % CI 0.818–0.945), respectively. Substantial heterogeneity was detected in this study
(I2 = 90 %). The publication bias was assessed by using Deeks’ asymmetry test (p = 0.795). No evidence of heterogeneity
from threshold effects was detected by the Spearman correlation coefficient (−0.506, p = 0.201). Meta-regression was
performed to mining the source of heterogeneity, and subgroup analysis showed that neither the cut-off values nor the
control groups were the source of heterogeneity.
Conclusions: The present results suggest that promoted CD44V6 expression levels are associated with OS and CD44V6
may be used as a diagnostic marker for OS.
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Background
Osteosarcoma (OS) is the most frequent primary non-
hematological bone tumor that mainly afflicts adoles-
cents, and the peak incidence is during the second
decade of life [1, 2]. Proximal tibia, proximal humerus,
and distal femur are the most common afflicted sites of
primary tumors [3]. The majority of OS patients have
high grade lesions and poor prognosis. As the second
leading cause of cancer associated death in young adults,
approximately 80 % of OS patients have metastatic
disease at the time of diagnosis [4]. Although plain
radiographic imaging is highly suggestive for OS diagno-
sis, only 10–15 % of these lesions are detectable with
current diagnostic tools [5].
Currently, the mechanism of oncogenesis and tumor
progression is still not fully elucidated, and this restricts
the diagnosis of OS. Many scientists endeavored to OS
diagnosis, prognosis, and treatment because effective
diagnostic biomarker and therapeutic methods used for
OS have not been discovered. Laboratory evaluation for
OS patients is generally normal, and the serum alkaline
phosphatase (ALP), phosphatase lactate dehydrogenase,
and MMP9 levels have been documented, unspecified,
and up-regulated in 40–50 % of patients [6]. After caner
resection, the levels of serum ALP are generally
decreased, but it is strongly suggested the recurrence
and metastasis when declined ALP values are elevated
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again [7]. Some researchers had suggested that identify-
ing ideal diagnostic markers in cancer would be valuable
for proper individual management. Therefore, it would
be urgently needed to explore more sensitive and
specific non-invasive biological biomarkers for early OS
diagnosis.
As a trans-membrane glycoprotein, CD44 has a cyto-
plasmic domain, a trans-membrane domain, and seven
extracellular domains [8]. CD44 variant isoform V6
(CD44V6) is one of the variant isoforms (CD44V), which
is reportedly associated with increased invasion, metas-
tasis, and poor prognosis of different neoplasms [9–12].
CD44V6 not only regulates the extracellular matrix and
promotes cell motility but also suppresses tumor apop-
tosis and promotes tumor progression. Although some
studies showing that CD44V6 confer a pivotal diagnostic
value in various solid tumors, the association between
CD44V6 and OS were still controversial. In order to
further validate the clinical applicability of CD44V6 for
OS, we conducted this systematic meta-analysis based
on all relevant studies.
Methods
Search strategy and selection criteria
The Cochrane Library, PubMed (MEDLINE), ISI Web of
Knowledge, ScienceDirect, Embase, BioMed Central, and
Springer together with three Chinese databases Weipu,
Wanfang, and China National Knowledge Internet
(CNKI) databases were used to conduct a comprehen-
sive computerized literature search for articles that
evaluated the accuracy of CD44V6 for the diagnosis of
OS. The studies were identified by using the following
keywords in variably combinations: “(osteosarcoma OR
bone tumor) and (CD44V6 OR CD44 variation 6).” In
addition to the electronic literatures that published
before April 23, 2016, the reference lists of primary stud-
ies and previous systematic reviews were also searched
for additional articles.
Quality assessment
The Quality Assessment of Diagnostic Accuracy Studies
checklist (QUADAS) were used to assess the methodo-
logical quality of the studies [13]. The guidelines for
scoring each item to our analysis were tailored [14]. In
summary, the involved articles were considered low risk
of bias according to the QUADAS criteria. Review proto-
col can be accessed on the site http://www.crd.york.ac.uk/
PROSPERO/ with registration number CRD42016037459.
Study selection criteria
Inclusion criteria are as follows: (1) measurement of
CD44V6 in OS using commercial reagents; (2) definite
diagnosis confirmed for newly diagnosed patients with
OS as the case group and patients with benign bone
tumor (BBD) or healthy people as the control group; (3)
studies with sufficient information to construct the 2 × 2
contingency table; (4) publications written in English or
Chinese.
Exclusion criteria are as follows: (1) literatures not per-
tinent to CD44V6; OS diagnosed without a biopsy and
there was no clear cut-off value in the literature; (2) no
control groups or control group is not BBD or healthy
people; (3) similar studies from the same author as well as
multiple duplicate data in the different works, excluding
earlier and smaller sample data; (4) animal experiments,
case reports, correspondences, reviews, expert opinions,
letters, talks, and editorials without original data.
Data extraction
Data was carefully extracted from all eligible studies in
duplicate by two independent investigators (YYZ and
XC). Extracted databases were crosschecked between the
two authors to rule out any discrepancy. Disagreement
was resolved by consulting with a third investigator. The
following data for each collected studies were extracted
independently: (1) basic information of articles (the first
author, publication year); (2) characterization of research
Fig. 1 Schematic representation of the study selection
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objects (sample size, assay kit, cut-off value); and (3)
data used to calculate the sensitivity and specificity of
each study (TP, FP, FN, TN). If any essential information
were not available from the article, best efforts were
made to sending a reminder to the corresponding
authors. The study was excluded if no response was
received after sending a reminder.
Statistical analysis
Stata 12.0 (Stata Corporation, College Station, TX, USA)
and Meta-DiSc 1.4 software were used for all statistical
analyses. The true positives, false negatives, false posi-
tives, and true negatives in each study were tabulated to
obtain pooled sensitivity (SEN), pooled specificity (SPE),
positive likelihood ratio (PLR), negative likelihood ratio
(NLR) and a corresponding CI. Summary receiver
operating characteristic curve (SROC) was used to
summarize the results [15, 16]. The respective area
under the SROC curve (AUC) and Q point value (Q)
were estimated to evaluate the accuracy of the diagnostic
test [16]. Generally, the score of AUC 0.93 to 0.96 is
regarded as very good, and 0.75–0.92 as good, but AUC
<0.75 can be still reasonable [17]. If heterogeneity
among studies was recorded by I2, the potential source
of heterogeneity was investigated by sensitivity ana-
lysis and meta-regression. Study specific covariates
such as cut-off values, control groups and assay kits
were used for investigated the meta-regression reason.
Deeks’ regression test and Spearman’s correlation
coefficient (rs) of log (SEN) and log (1-SPE) were
used to inspect publication bias.
Results
Study characteristics
As a result of electronic databases search, 764 published
records associated with the diagnostic value of CD44V6
in OS were retrieved. 648 articles were left after dupli-
cated data removed. After reviewing the titles and ab-
stracts, we excluded another 626. After a full text review
we excluded a further 14, finally, 8 studies [18–25] were
included in our study (Fig. 1). As shown in Table 1, the
expression level of CD44V6 was detected by immuno-
histochemistry (IHC) in all studies and the results were
judged by cut-off value in 2 ways: immunoreactivity score
(IRS) or positivity percentage. According to Enneking
System, 4 of 8 articles reported classification of clinical
stages [26] (stages 1, 2, and 3; Table 2).
Diagnostic accuracy of CD44V6 in discriminating OS from
healthy controls or BBD
Table 1 shows the accuracy of the CD44V6 in discrimin-
ating OS from healthy controls or benign bone disease
(BBD). A total of 8 studies involving 651 participants
(463 OS patients, 40 healthy controls, and 148 BBD con-
trols) were included in the pooled analysis. The pooled
sensitivity was 0.743 (95 % CI 0.606–0.844) (Fig. 2), and
pooled specificity was 0.897 (95 % CI 0.818–0.945)
(Fig. 3). The AUC was 0.91 (95 % CI 0.88–0.93), and the
Table 1 Main characteristics of 8 studies
Author Year Assay kit n Case of OS Case of control Prevalence (%) Cut-off TP FP FN TN
H BBD
Chen et al. 2001 Maxim 100 70 15 15 70 % 2 score 64 2 6 28
Liu et al. 2002 Boshide 55 30 10 15 55 % 25 % 28 1 2 24
Guo et al. 2007 Zhongshan 69 49 – 20 71 % 5 % 27 5 22 15
Li et al. 2008 Maxim 65 35 15 15 54 0 % 19 2 16 28
Yang et al. 2008 Boshide 56 36 – 20 64 5 % 26 0 10 20
Hu et al. 2009 Santa cruz 107 87 – 20 81 3 score 45 4 42 16
Deng et al. 2013 Maixin 110 90 – 20 82 3 score 59 5 31 15
Zhu et al. 2014 Zhongshan 89 66 – 23 74 5 % 56 2 10 21
Table 2 Summary characteristics of 5 studies
Author Year Case of stage 1 Case of stage 2 Case of stage 3 Case of control
TP FN TP FN TP FN FP TN
Chen et al. 2001 2 1 59 20 3 0 2 28
Liu et al. 2002 4 1 20 0 1 1 1 24
Li et al. 2008 2 7 9 6 8 3 2 28
Hu et al. 2009 20 22 12 13 13 7 4 16
Zhu et al. 2014 – – 38 7 18 3 2 10
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diagnostic odds ratio (DOR) was 25.267 (95 % CI 8.029–
79.574) (Fig. 4). Pooled negative likelihood ratio (NLR)
was 0.286 (95 % CI 0.172–0.477), and pooled positive
likelihood ratio (PLR) was 7.239 (95 % CI 3.586–14.611).
We also tested the diagnostic accuracy of CD44V6 as a
biomarker for OS at different stages, as it is shown in
Table 3, the diagnostic sensitivity of CD44V6 was
increasing with the malignancy of OS from 47 to 75 %,
while the diagnostic specificity has no changes (91 %).
Heterogeneity analysis
Substantial heterogeneity was detected among those
studies by I2 (I2 = 90 %, p = 0.000). Generally, when I2 >
50%, it is considered as heterogeneity. So, we used the
random effect model to calculate combined effect indi-
cators. Sensitivity analysis was conducted to investigate
the influence of any single study. No significant differ-
ence was found after remove of any single study,
suggesting that the conclusions are stable.
Publication bias
Publication bias was not found by Deeks’ regression
test (p = 0.795) (Fig. 5). The shapes of the funnel plots
did not reveal any evidence of obvious asymmetry.
The Spearman correlation coefficient indicated that
there is no heterogeneity from threshold effects
(−0.506, p = 0.201).
Possible sources of heterogeneity and subgroup analysis
Next, meta-regression analyses were then used to iden-
tify the sources of heterogeneity. Cut-off values, control
groups, and assay kits were considered as the reason-
able factors of heterogeneity. After meta-regression
analysis, we found neither the cut-off values nor the
control groups was the source of heterogeneity (Tables 4
Fig. 2 Sensitivity of CD44V6 assay for osteosarcoma
Fig. 3 Specificity of CD44V6 assay for osteosarcoma
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Fig. 4 Summary receiver operating characteristic curve
Fig. 5 Deeks’ regression test of publication bias
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and 5), p value for cut-off values was 0.139 (STATA) or
0.492 (Meta-DiSc); p value for control groups (STATA)
was 0.646 or 0.186 (Meta-DiSc), respectively. Five
sources of assay kits (Santa Cruz diagnostics, Maxim,
Boshide, Zhongshan, and MAIXIN) were used in 8
studies, and the number of subgroups is not enough to
be conducted with meta-regression analysis. Further
studies are warranted to confirm whether assay kits are
the sources of heterogeneity.
CD44V6 may be used as a diagnostic marker for OS
Our data shows the positive likelihood ratio is 7.239,
which means the OS patients are 7.239 times to have
CD44V6 positive result than controls. In order to de-
scribe Fagan plot result (Fig. 6), the pre-test probability
and the post-test probability were linked by a straight
line crossing the likelihood ratio. When 20 % was chosen
as the pre-test probability, the post-test probability for
CD44V6 positive result is 64 % as a result. Similarly, the
post-test probability for CD44V6 negative result was re-
duced to 7 % with the negative likelihood ratio of 0.29.
In conclusion, CD44V6 may be used as a diagnostic
maker for OS.
Discussion
CD44, one of the members of cell adhesion molecules,
control cell behavior by mediating contact between cells
and the extracellular matrix and are therefore involved
in pathological conditions including tumor progression
and metastasis [27, 28]. As one of the variant forms of
CD44, CD44V6 has been noted to associate with cell ad-
hesion, proliferation, differentiation, and survival and are
thereby prone to be involved in tumor progression. For
example, CD44V6 has been shown to regulate cell
proliferation through MAPK signaling pathway [26].
Additionally, CD44V6 could also suppress tumor apop-
tosis and facilitate tumor progression through PI3K/Akt
signaling pathway. Nakajima and association discovered
that CD44V6 may act as an onco-protein in the metasta-
sized OS [29]. Considering that CD44V6 is conspicuous
and homogeneous expression within malignant tumors,
antibodies recognizing CD44V6 were used in clinical tri-
als for patients suffering from head and neck squamous
cell carcinoma (HNSCC). Although the phase I clinical
trials looked promising, the studies were abruptly with-
drawn after the death of a patient due to skin-related
toxicities [30]. Despite the termination of the trials, the
onco-genetic role of CD44V6 certainly correlates with
aggressive stages of various human cancers. According
to the published data, high levels of CD44V6 have been
detected in most kinds of carcinomas, such as prostate
cancer [31], non-Hodgkin’s lymphomas [32], ovarian
cancer [33], cervical cancer [34], and OS [35]. As a result
of electronic database search, increasing evidence has
showed that high expression of CD44V6 was suggested
to be associated with OS. But the small sample size is
the limitation of all involved articles. To further explore
the relationship between CD44V6 expression levels with
OS, the present meta-analysis was conducted to deter-
mine whether CD44V6 can be used as a putative diag-
nostic biomarker for OS.
Eight literatures including 463 cases and 188 controls
have been combined in the present meta-analysis. Over-
all, the results showed SEN of 0.743 (95 % CI 0.606–
0.844) and SPE of 0.897 (95 % CI 0.818–0.945), while
PLR of 7.239 (95 % CI 3.586–14.611) NLR of 0.286
(95 % CI 0.172–0.477), respectively. The DOR combined
the pooled sensitivity and specificity was 25.267, which
means CD44V6 could be a promising biomarker in the
diagnosis of OS. We then calculated the AUC to assess
the diagnostic accuracy of CD44V6 in discriminating OS
from controls. An AUC of CD44V6 to OS is 0.91 means
a good diagnostic accuracy. The diagnostic value of
CD44V6 for OS in different clinical stages was also ana-
lyzed. Although pooled specificity is 91 % despite the
pathological stage, pooled sensitivity of CD44V6 was in-
creasing with the malignancy of OS from 47 to 75 %.
Heterogeneity has significant impact on interpreting
the results from the meta-analysis. After analyzed with
the Deeks’ regression test and Spearman correlation co-
efficient, no evidence of publication bias was detected.
Additionally, sensitivity analysis suggests that the diag-
nostic parameters do not overly rely on one study, which
confirmed the robustness of this analysis. Therefore, the
Table 4 Univariable bivariate mixed-effects binary meta-regression
Subgroup MIDAS (p value) Meta-DiSc
RDOR p value
Cut-off value 0.139 2.67 0.492
Control group 0.646 0.14 0.186
Table 3 Summary diagnostic accuracy of CD44V6 for osteosarcoma in different clinical stages
Stage Number of studies Case of OS Case of control Pooled sensitivity (95 % CI) Pooled specificity (95 % CI) AUC (Q)
Stage 1 4 77 105 0.47 (0.34–0.41) 0.91 (0.84–0.96) 0.91 (0.84)
Stage 2 5 184 118 0.75 (0.68–0.81) 0.91 (0.84–0.95) 0.95 (0.87)
Stage 3 5 57 118 0.75 (0.62–0.86) 0.91 (0.84–0.95) 0.89 (0.82)
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source of heterogeneity was then explored by meta-
regression. From the data which extracted from the
included papers, the cut-off values, control groups and
assay kits, were selected to investigate the sources of
heterogeneity. After meta-regression analysis, the results
show that neither cut-off values nor the control groups
are the main source of heterogeneity. Five sources of
assay kits were used in 8 studies, and the reagent
grouped number is not enough to be performed by
meta-regression analysis.
To our knowledge, this is the first meta-analysis and
systematic review in summarizing the values of CD44V6
in OS diagnosis. Although our results revealed that
CD44V6 was an ideal diagnostic marker of OS, we
should prudentially make the conclusion of the associ-
ation with CD44V6 and OS for some potential limita-
tions. First, because the rarity of primary malignant
tumors of the bone, accounting for approximately 0.2 %
of all malignancies, the numbers of articles involved in
our analysis were relative small, which may weaken the
reliability of our results. In future, multicenter trials with
larger sample size might need to confirm our results and
explore potential factors that may influence diagnostic
accuracy. Second, prominent heterogeneity maybe con-
taminate our analysis results. The heterogeneity was
probably due to the cut-off values, control groups, assay
kits and others. Under this condition, we try to weaken
their effects by using a random effect model.
Table 5 Summary data of subgroup analysis






Percentage 5 216 118 0.72 (0.66–0.78) 0.92 (0.85–0.96) 0.93 (0.86)
Score 3 247 70 0.68 (0.62–0.74) 0.84 (0.74–0.92) 0.95 (0.90)
Control
Health 3 135 40 0.82 (0.75–0.88) 0.94 (0.87–0.98) 0.98 (0.94)
BBD 5 328 148 0.65 (0.60–0.70) 0.84 (0.76–0.91) 0.74 (0.68)
Fig. 6 Fagan nomogram of the CD44V6 test for diagnosis of osteosarcoma
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In summary, despite some limitations mentioned above,
our meta-analysis indicated that the elevated CD44V6
expression is significantly associated with OS patients.
More clinical studies with larger sample size should be
carried out before CD44V6 could be applied to a diagnos-
tic marker in the routine clinical guidance of OS.
Conclusions
In conclusion, the present results suggest that promoted
CD44V6 expression levels are associated with OS and
CD44V6 may be used as a diagnostic marker for OS.
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